# A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

> **NCT06191991** · PHASE1 · COMPLETED · sponsor: **Aligos Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** ALG-055009
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT06191991
- **Lead sponsor:** Aligos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-03
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-12-04
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06191991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06191991, "A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06191991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*